Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.37 |
| ▸ | ACACA | Q13085 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24670928 | 0.94 | ITK (0.53) | ITKKDRPIP5K1CTLR9TLR8 | |
| SCHEMBL29990522 | 0.94 | ITK (0.53) | ITKKDRPIP5K1CTLR9TLR8 | |
| SCHEMBL30863357 | 0.87 | ITK (0.54) | ITKPIP5K1CRIPK1MET | |
| SCHEMBL12027720 | 0.86 | ITK (0.53) | ITKKDRPIP5K1CRIPK1MET | |
| SCHEMBL30066189 | 0.85 | ITK (0.50) | ITKKDRPIP5K1C | |
| SCHEMBL24670789 | 0.85 | ITK (0.50) | ITKKDRPIP5K1C | |
| SCHEMBL30801176 | 0.85 | ITK (0.50) | ITKKDRPIP5K1C | |
| SCHEMBL12027721 | 0.85 | ITK (0.62) | ITKKDRPIP5K1CFLT3RIPK1 | |
| Hydrochloric Acid SCHEMBL29207704 | 0.85 | ITK (0.49) | ITKKDRPIP5K1C | |
| SCHEMBL24670722 | 0.85 | ITK (0.51) | ITKPIP5K1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | ITK 1/4885KDR 2126/4885PKM 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.